Nivolumab following CAR-T failure in multiple myeloma and non-Hodgkin lymphoma: results of a phase 2 study

Abstract: We conducted a single-center open-label phase 2 trial of the programmed cell death protein 1 (PD-1) inhibitor nivolumab for patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) following failure of last-line chimeric antigen receptor T-cell (CAR-T) therapy. The primary end poi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Rahul Banerjee, Sylvain Simon, Jenna M. Voutsinas, Qian Vicky Wu, Daria Gausman, Joshua Dizon, Ethan Xie, Cecilia C. S. Yeung, Minggang Lin, Ryan C. Lynch, Chaitra S. Ujjani, Brian G. Till, Mary L. Kwok, Sarah S. Lee, Rebecca Silbermann, Eva Medvedova, Peter Wilcox, Jorge Ramos, Mazyar Shadman, Jordan Gauthier, Cameron J. Turtle, Damian J. Green, Ajay K. Gopal, Stanley R. Riddell, Andrew J. Cowan
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-03-01
Serie:	Blood Immunology & Cellular Therapy
Accesso online:	http://www.sciencedirect.com/science/article/pii/S3050597625000223
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!